261 related articles for article (PubMed ID: 34393077)
21. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
22. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
[TBL] [Abstract][Full Text] [Related]
25. Secondary organizing pneumonia after recovery of mild COVID-19 infection.
Golbets E; Kaplan A; Shafat T; Yagel Y; Jotkowitz A; Awesat J; Barski L
J Med Virol; 2022 Jan; 94(1):417-423. PubMed ID: 34581458
[TBL] [Abstract][Full Text] [Related]
26. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient.
Baang JH; Smith C; Mirabelli C; Valesano AL; Manthei DM; Bachman MA; Wobus CE; Adams M; Washer L; Martin ET; Lauring AS
J Infect Dis; 2021 Jan; 223(1):23-27. PubMed ID: 33089317
[TBL] [Abstract][Full Text] [Related]
27. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
Rodriguez-Pla A; Vikram HR; Khalid V; Wesselius LJ
Rheumatol Int; 2021 Aug; 41(8):1509-1514. PubMed ID: 34091704
[TBL] [Abstract][Full Text] [Related]
29. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature.
Tepasse PR; Hafezi W; Lutz M; Kühn J; Wilms C; Wiewrodt R; Sackarnd J; Keller M; Schmidt HH; Vollenberg R
Br J Haematol; 2020 Jul; 190(2):185-188. PubMed ID: 32557623
[TBL] [Abstract][Full Text] [Related]
30. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
31. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma.
Levi G; Rocchetti C; Magri R; Uccelli S; Bottone D; Quadri F; Novali M; Santin AD; Bezzi M
Monaldi Arch Chest Dis; 2021 Jun; 91(4):. PubMed ID: 34121379
[TBL] [Abstract][Full Text] [Related]
32. Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature.
Omura Y; Shimazu H; Takahashi T
Intern Med; 2018 Apr; 57(8):1151-1154. PubMed ID: 29269668
[TBL] [Abstract][Full Text] [Related]
33. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies.
Milunović V; Bogeljić Patekar M; Jakubac KM; Mandac Rogulj I; Radić-Krišto D; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2017 Mar; 56(1):143-156. PubMed ID: 29120553
[TBL] [Abstract][Full Text] [Related]
34. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
Moccia AA; Zucca E; Ghielmini M
Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
[TBL] [Abstract][Full Text] [Related]
35. The known unknowns of T cell immunity to COVID-19.
Karlsson AC; Humbert M; Buggert M
Sci Immunol; 2020 Nov; 5(53):. PubMed ID: 33208380
[TBL] [Abstract][Full Text] [Related]
36. Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases.
Martínez-Chinchilla C; Vazquez-Montero L; Palazón-Carrión N; Fernández-Román IM; López-Barba J; de la Cruz-Merino L; Rodríguez-Baño J; Palacios-Baena ZR
Front Immunol; 2022; 13():860891. PubMed ID: 35493500
[TBL] [Abstract][Full Text] [Related]
37. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
38. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Cattaneo C; Cancelli V; Imberti L; Dobbs K; Sottini A; Pagani C; Belotti A; Re A; Anastasia A; Quaresima V; Tucci A; Chiorini JA; Su HC; Cohen JI; Burbelo PD; Rossi G; Notarangelo LD
Blood Cancer J; 2021 Sep; 11(9):151. PubMed ID: 34521813
[TBL] [Abstract][Full Text] [Related]
39. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
40. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
